A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline | Zendy

N Claire Gordon | Zendy; David W. Wareham | Zendy

Open Access

A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline

Author(s) -

N Claire Gordon,

David W. Wareham

Publication year - 2009

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkn555

Subject(s) - tigecycline , acinetobacter baumannii , acinetobacter , medicine , multiple drug resistance , microbiology and biotechnology , intensive care medicine , drug resistance , antibiotics , biology , bacteria , pseudomonas aeruginosa , genetics

Multidrug-resistant Acinetobacter baumannii (MRAB) is an increasing problem in UK hospitals, with many strains now resistant to all available antibiotics except polymyxins. Tigecycline has been used for the treatment of MRAB as it demonstrates activity in vitro, but there are limited data on its clinical efficacy in Gram-negative infections, especially those involving the lower respiratory tract or bacteraemia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research